Literature DB >> 6322565

Comparison of oral MK 421 and propranolol in mild to moderate essential hypertension and their effects on arterial and venous vessels of the forearm.

A C Simon, J A Levenson, J D Bouthier, A Benetos, A Achimastos, M Fouchard, B C Maarek, M E Safar.   

Abstract

The efficacy of MK 421 and propranolol was compared in 48 patients with mild to moderate hypertension. Each patient was randomly assigned to receive 1 of the drugs for 12 weeks. Additionally, a subgroup of 28 patients underwent studies of forearm arterial and venous circulation by means of pulsed Doppler and mercury-in-silastic plethysmography. Both drugs reduced supine and standing blood pressure (BP) (p less than 0.001). Propranolol reduced heart rate (p less than 0.001), while MK 421 did not change it. Brachial artery diameter, blood velocity and flow increased after MK 421 (p less than 0.001), but were not changed after propranolol therapy. Forearm vascular resistance decreased after MK 421 (p less than 0.001) and after propranolol (p less than 0.05). Forearm venous tone was unaffected on MK 421, but increased after propranolol (p less than 0.01). Thus, in moderate hypertension, 3 months of treatment with MK 421 or propranolol similarly decrease BP, but affect the forearm circulation differently: MK 421 dilates both the brachial artery and the arterioles of the forearm, but does not affect the venous vessels, and propranolol causes little arterial change but increases the forearm venous tone.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6322565     DOI: 10.1016/0002-9149(84)90403-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

Review 1.  Newer beta blockers and the treatment of hypertension.

Authors:  D McAreavey; R Vermeulen; J I Robertson
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

Review 2.  Mechanism of action of angiotensin-converting enzyme (ACE) inhibitors in hypertension and heart failure. Role of plasma versus tissue ACE.

Authors:  V J Dzau
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 3.  Heterogeneity of response of peripheral arteries to antihypertensive drugs in essential hypertension. Basic effects and functional consequences.

Authors:  J Levenson; A Simon
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  A comparison of amlodipine with enalapril in the treatment of isolated systolic hypertension.

Authors:  J Webster; G Fowler; T A Jeffers; D Lyons; K Witte; W A Crichton; E A Wickham; S S Sanghera; R Cornish; J C Petrie
Journal:  Br J Clin Pharmacol       Date:  1993-05       Impact factor: 4.335

5.  Efficacy of enalapril in essential hypertension and its comparison with atenolol.

Authors:  M el Mangoush; N K Singh; S Kumar; A Basha; B S Gupta; Y K Bolya; A Gamati
Journal:  Postgrad Med J       Date:  1990-06       Impact factor: 2.401

6.  Comparison of enalapril and propranolol in essential hypertension.

Authors:  B A van Schaik; G G Geyskes; N Kettner; P Boer; E J Mees
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 7.  Enalapril in hypertension and congestive heart failure. Overall review of efficacy and safety.

Authors:  F Moncloa; J A Sromovsky; J F Walker; R O Davies
Journal:  Drugs       Date:  1985       Impact factor: 9.546

8.  Effects of the single and repeated administration of benazepril on systemic and forearm circulation and cardiac function in hypertensive patients.

Authors:  N De Luca; S Savonitto; B Ricciardelli; R Marchegiano; F Lamenza; G Lembo; B Trimarco
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

Review 9.  ACE inhibition and brachial artery haemodynamics in hypertension.

Authors:  A C Simon; J A Levenson; A M Safar; J D Bouthier; M E Safar
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

Review 10.  An overview of the clinical pharmacology of enalapril.

Authors:  R O Davies; H J Gomez; J D Irvin; J F Walker
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.